Biogen Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Biogen Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 7.3 times. Higher than 92% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$162Over the last 3 years, every $100 of reported profit came with $162 of operating cash.
Higher than 58% of Healthcare companies in United States.
Self-Funding Ratio
7.3×Over the last 3 years its own operating cash covered its investment spending (capex) 7.3 times.
Higher than 92% of Healthcare companies in United States.
Cash Locked Ratio
$35For every $100 of sales, $35 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $27 tied up three years earlier.
More money tied up than 75% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by -3% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
-3% / +20%In 3 years sales changed by -3% while total assets changed by +20%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
−7%Debt, after subtracting cash, equals 7% of its market value (net debt).
Lower than 77% of Healthcare companies in United States.
Tangible Assets Ratio
47%Of every $100 the company owns, $47 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 84% of Healthcare companies in United States.
Tangible Net Worth Ratio
14%Of every $100 of net worth, $14 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 67% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Biogen Inc. owes $0.41 for every $1 it owns. Net profit fell 21% in the year to Dec 2025, and shrank 25% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
44.5Investors pay $44.5 for every $1 of Biogen Inc.'s yearly profit, higher than 77% of Healthcare companies in United States.
P/B ratio
1.97The share price is 1.97 times Biogen Inc.'s book value per share, lower than 59% of Healthcare companies in United States.
Market cap
$37.0 BThe total market value of all of Biogen Inc.'s shares at today's price (share price × number of shares), larger than 95% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$18.8 BWhat Biogen Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$127.56Net worth divided by the number of shares. The share price of $250.69 is 2.0 times this, which is the P/B above.
Return on equity (ROE)
4.6%Biogen Inc. earned 4.6% on its shareholders' money over the last year, higher than 79% of Healthcare companies in United States.
Owes vs Owns
0.41×Biogen Inc. owes $0.41 for every $1 it owns (low), higher than 50% of Healthcare companies in United States.
Dividend yield
NoneBiogen Inc. does not currently pay a dividend.
Revenue growth
+2%Revenue rose 2% in the year to Dec 2025, and shrank 1% a year on average over 3 years.
Profit growth
-21%Net profit fell 21% in the year to Dec 2025, and shrank 25% a year on average over 3 years.
Profit margin
13.1%Biogen Inc. keeps $13 of every $100 of revenue as net profit.
Cash quality
1.7×Cash from Biogen Inc.'s business was 1.7× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
9.2×Biogen Inc.'s operating profit covered its interest costs 9.2 times in the year to Dec 2025.
Cash vs debt
Net debtBiogen Inc. had $2.8 B more debt than cash (net debt) at Dec 2025.
Questions
What is Biogen Inc.'s P/E ratio?
Investors pay $44.5 for every $1 of Biogen Inc.'s yearly profit, higher than 77% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Biogen Inc.: $37.0 B ÷ $18.8 B (30 Jun 2026) = 2.0.
What is Biogen Inc.'s return on equity?
Biogen Inc. earned 4.6% on its shareholders' money over the last year, higher than 79% of Healthcare companies in United States.
How much does Biogen Inc. owe compared with what it owns?
Biogen Inc. owes $0.41 for every $1 it owns (low), higher than 50% of Healthcare companies in United States.
Does Biogen Inc. pay a dividend?
No. Biogen Inc. does not currently pay a dividend.
Is Biogen Inc.'s revenue growing?
Revenue rose 2% in the year to Dec 2025, and shrank 1% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.